DCTH trading ideaIt appears triangle is forming in wave 4. which is about to
complete.
Based on it, we can have some trade plan
Buy DCTH at 0.1273, stop loss 0.1183, target 0.2571 and above, check red lines for 3 upside targets
Key stats
Market capitalization
48.625MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.79USD
About Delcath Systems, Inc
ISIN
US24661P8077
Sector
Health Technology
Industry
Medical Specialties
Website
delcath.com
CEO
Gerard J. Michel
Headquarters
New York
Employees
55
Founded
1988
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0